Congress Materials – European Lung Cancer Conference (ELCC 2025)
2025 European Lung Cancer Conference | March 26-29 | Paris, France
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
Amivantamab Plus Lazertinib vs Osimertinib in First-line EGFR-mutant Advanced NSCLC Final Overall Survival from the Phase 3 MARIPOSA Study
James Chih-Hsin Yang, Yu Jung Kim, Se-Hoon Lee, Baogang Liu, Yurii Ostapenko, Shun Lu, Adlinda Alip, Ernesto Korbenfeld, Josiane Mourão Dias, Pongwut Danchaivijitr, Nicolas Girard, Enriqueta Felip, Hidetoshi Hayashi, Alexander I. Spira, Benjamin Besse, Tao Sun, Mariah Ennis, Seema Sethi, Joshua M. Bauml, Byoung Chul Cho
Preventing Moderate to Severe Dermatologic Adverse Events in First-line EGFR-mutant Advanced NSCLC Treated with Amivantamab Plus Lazertinib - Early Success of the COCOON Trial
Nicolas Girard, Weimin Li, Alexander I. Spira, Jill Feldman, Milena Mak, Maxwell Sauder, Weimin Li, Farastuk Bozorgmehr, Pei Jye Voon, Cheng-Ta Yang, Juan Esteban Cundom, Jorge Nieva, Pascale Tomasini, Irfan Cicin, Bailey G. Anderson, Tonatiuh Romero, Shubin Sheng, Joshua M. Bauml, Jairo Simoes, Parthiv J. Mahadevia, Byoung Chul Cho
Subcutaneous after intravenous amivantamab in advanced NSCLC: Initial results from PALOMA-2
Sun Min Lim, Ji-Youn Han, Jun Zhang, Eldsamira Mascarenhas, Carlos Henrique Andrade Teixeira, Nicolas Girard, Nir Peled, Susan C Scott, Martin Gutierrez, Alessandra Bulotta, Jiunn Liang Tan, Tarek Mekhail, Dana-Adriana Botesteanu, Ali Alhadab, Janine Mahoney, Miao Wang, Jie Zhang, Julia Schuchard, Mahadi Baig, Flavia Amaral Duarte
Evaluating the effectiveness of amivantamab plus lazertinib in CHRYSALIS-2 vs EGFR TKI monotherapy in a matched real-world cohort of participants with atypical EGFR-mutated advanced NSCLC
Pascale Tomasini, Yongsheng Wang, Se-Hoon Lee, Jiuwei Cui, Enriqueta Felip, Alexander I. Spira, Yongsheng Li, Lin Wu, Sebastian Michels, Eiki Ichihara, Joel W. Neal, Levon Demirdjian, Craig S. Meyer, Youyi Zhang, Hemanth Kanakamedala, Anthony Louder, Leonardo Trani, Isabelle Leconte, Mahadi Baig, Byoung Chul Cho
Real-World Treatment Patterns Among Patients With Advanced NSCLC Treated With Amivantamab
David Waterhouse, Iris Lin, Laura Morrison, Bruno Emond, Marie-Hélène Lafeuille, Yuxi Wang, Lilian Diaz, Patrick Lefebvre, Dexter Waters
FIN-EGFRprint: A Retrospective Observational Study to Investigate Treatments and Outcomes in Patients With Epidermal Growth Factor Receptor-Mutated (EGFRm) Advanced Non-Small Cell Lung Cancer (aNSCLC) in Finland
Aija Knuuttila, L. Nurmi, P. Vänni, J. Edwards, M. Ekblom, I. Luccarini, M. Silvoniemi
NBTXR3 Activated by SBRT in Combination With Nivolumab or Pembrolizumab for the Treatment of Patients With Lung Metastases From NSCLC or Other Solid Tumors in the Phase I Trial Study 1100
Colette Shen, Aditya Juloori, William A. Stokes, Jason Akulian, Jared Weiss, Kedar Kirtane, Laurent Mayrargue, David Rolando, Roman Gineste, Omar I. Vivar, George Q. Yang, Jimmy Caudell, Ammar Sukari, Nabil F. Saba, Septimiu Murgu, Ari Rosenberg
The FIN-EGFR study: A retrospective observational study to investigate the treatment landscape and outcomes of early and advanced stage patients with EGFR mutated non-small cell lung cancer (NSCLC) in Finland
Aija Knuuttila, Lalli Nurmi, Monica Ekblom Anna Bonin, Eija Heikkilä and Maria Silvoniemi
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.